Gemfibrozil oxime derivative and its use as FXR antagonist
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- SHANGHAI INST OF PHARMA IND
- Publication Date
- 2017-03-08
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the field of new drug design and synthesis, and in particular relates to a gemfibrozil oxime derivative, its preparation method and its application as an FXR antagonist. Background technique
[0002] Cardiovascular and cerebrovascular diseases are currently one of the most serious diseases that endanger human life and health. They are common and frequently-occurring diseases of middle-aged and elderly people, and rank first in morbidity and mortality in many countries. Atherosclerosis is the basis of many cardiovascular and cerebrovascular diseases. A large number of experimental and clinical data prove that atherosclerosis is closely related to abnormal blood lipid metabolism. Therefore, blood lipid regulation has become an important field in the current research of this type of new drug.
[0003] Through prospective, random and controlled clinical studies, it has been proved that some statins can reduce the occurrence of ath...